RSV
ID News Round-Up
Advances in infectious disease prevention and treatment have made headlines on COVID-19, flu, HPV, RSV, and more
Schaffner Report: What Adults Should Know about New RSV Vaccines
NFID Medical Director William Schaffner, MD, talks with NFID Executive Director and CEO Marla Dalton, CAE, about new vaccines for RSV
Expert Insights on Advances in RSV Prevention and Treatment
New tools for the prevention and treatment of respiratory syncytial virus (RSV) are moving through the development pipeline
Experts to Explore Advances in RSV, COVID-19, and Flu Prevention and Treatment
Annual Conference on Vaccinology Research will feature latest science
Monoclonal Antibodies Fact Sheet (Spanish)
Spanish fact sheet provides information on monoclonal antibodies (mAbs) and the differences between vaccines and mAbs
NFID Releases Progress Report on Respiratory Syncytial Virus (RSV) Prevention and Treatment
NFID has issued a new report on current efforts and progress in addressing respiratory syncytial virus (RSV) in the US
ID News Round-Up: Research Breakthroughs and Health Advisories
Read recent news of interest from the world of infectious diseases, with a focus on new research on long COVID; health alerts on Candida auris, dengue fever, and Marburg virus; and vaccines for pneumococcal disease and respiratory syncytial virus (RSV) …
Progress Report: Reducing the Burden of RSV across the Lifespan
NFID Progress Report provides updates on advancements in the development of potential interventions and additional disease surveillance, as well as concerning trends in respiratory syncytial virus (RSV) activity in the US in 2022-2023
Respiratory Syncytial Virus (RSV)
RSV is a respiratory virus that infects the lungs and breathing passages and can be serious, especially for infants and older adults
Susan’s Story (RSV)
After battling RSV for several months, Susan hopes to raise awareness about the potential danger of RSV in causing serious health complications in older adults